Immune-mediated heparin-induced thrombocytopenia
ICD-10 D75.822 is a billable code used to indicate a diagnosis of immune-mediated heparin-induced thrombocytopenia.
Immune-mediated heparin-induced thrombocytopenia (HIT) is a serious condition characterized by a decrease in platelet count following exposure to heparin, a common anticoagulant. This condition arises due to the formation of antibodies against complexes of heparin and platelet factor 4 (PF4), leading to platelet activation and increased risk of thrombosis. Patients may present with thrombocytopenia, typically defined as a platelet count of less than 150,000 platelets per microliter of blood, occurring 5 to 14 days after heparin exposure. HIT can lead to severe complications, including venous and arterial thrombosis, which can result in limb ischemia or organ dysfunction. Diagnosis is often confirmed through laboratory tests that detect anti-PF4/heparin antibodies. Management includes immediate cessation of heparin and initiation of alternative anticoagulation strategies. Understanding the nuances of HIT is critical for healthcare providers, as timely recognition and treatment can significantly impact patient outcomes.
Detailed patient history including heparin exposure, laboratory results, and clinical symptoms.
Patients presenting with thrombocytopenia after heparin therapy, requiring differential diagnosis.
Ensure clear documentation of the timing of heparin administration relative to the onset of thrombocytopenia.
Comprehensive assessment of patient history, including medication history and clinical findings.
Management of patients with suspected HIT in the context of other comorbidities.
Documentation should reflect the multidisciplinary approach to managing complications of HIT.
Used to monitor platelet levels in patients suspected of HIT.
Document the reason for the platelet count and any relevant clinical findings.
Hematology specialists should ensure that the clinical context is clear in documentation.
The primary cause of HIT is the formation of antibodies against the heparin-PF4 complex, leading to platelet activation and a decrease in platelet count.
